Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
@article{ATM74443,
author = {Fan Yang and Yu Fu and Arun Kumar and Mingsheng Chen and Lei Si and Sirikan Rojanasarot},
title = {Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China},
journal = {Annals of Translational Medicine},
volume = {9},
number = {15},
year = {2021},
keywords = {},
abstract = {},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/74443}
}